Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins.
To continue reading click here
Promega unveils cellular target engagement technology aimed at expanding the druggable proteome at SLAS 2026
